Compound Profiles
CJC-1295 (without DAC)
Short-Acting Growth Hormone Releasing Hormone Analog
Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.
Tesamorelin
GHRH Analog | Visceral Fat Reduction
Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat..
Combined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take CJC-1295 (without DAC) with Tesamorelin?
Yes, but with caution. Both are GHRH analogs; combining offers no additional benefit. Regular monitoring is advised.
Is CJC-1295 (without DAC) and Tesamorelin safe together?
Based on documented research, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting, teratogenic. Monitor accordingly.
What are the interactions between CJC-1295 (without DAC) and Tesamorelin?
Both are GHRH analogs; combining offers no additional benefit. This assessment has 90% confidence and is based on documented research data.
How should I time CJC-1295 (without DAC) and Tesamorelin?
CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and Tesamorelin has a half-life of 26-38 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.